SAM
PTGX icon

Shell Asset Management’s Protagonist Therapeutics PTGX Stock Holding History

Shell Asset Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,329
Closed -$107K – 1482
2020
Q4 		$107K Buy
+5,329
New +$115K ﹤0.01% 1260

Other funds holding PTGX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Shell Asset Management's PTGX Position: Q1 2021 in Review

Shell Asset Management sold out of Protagonist Therapeutics (PTGX) in Q1 2021, closing a stake of 5,329 shares — an estimated $107K sold.

Shell Asset Management first reported a position in PTGX in Q4 2020 and held it in 1 quarter. The position peaked at $107K in Q4 2020. 127 funds tracked by Wall St. Rank hold PTGX as of Q1 2021.

  • Shell Asset Management reported no remaining Protagonist Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Shell Asset Management sold 5,329 Protagonist Therapeutics shares in Q1 2021, an estimated $107K.
  • Shell Asset Management first reported a position in Protagonist Therapeutics in Q4 2020 and held it in 1 quarter.
  • Shell Asset Management's Protagonist Therapeutics position peaked at $107K in Q4 2020.
  • 127 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2021.

Based on Shell Asset Management's 13F filing for Q1 2021, filed 10 May 2021.